A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma: An ECOG study

摘要: Of 86 patients entered in an Eastern Cooperative Oncology Group (ECOG) random Phase II study of mitoxantrone (DHAD) and cisplatin (DDP) primary liver cancer, 69 were eligible. Nine the 13 ineligible excluded after a pathology review. Sixty-one percent North American, 39% South African. The most common severe or worst toxicity on DHAD was hematologic; to DDP, hematologic vomiting. eligible patients, 21 experienced severe, life-threatening fatal toxic reactions. Two treated with DDP had partial responses. With 95% confidence interval, true response rate less than 8%, 17%. median survival time 14 weeks both drugs. Assuming proportional hazards model, factors that are significantly associated patient performance status, presence symptoms, raised bilirubin hepatomegaly, clinical evidence cirrhosis. Any differences between rates for African American largely explainable by these factors.